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Abstract: Background: Insulin resistance (IR), a key characteristic of type 2 diabetes (T2DM), is mani-
fested by decreased insulin-stimulated glucose transport in target tissues. Emerging research has high-
lighted transient receptor potential cation channel subfamily V member (TRPV1) activation by cap-
saicin as a potential therapeutic target for these conditions. however, there are limited data on the
effects of capsaicin on cell signalling molecules involved in glucose uptake. Methods: C2C12 cells
were cultured and differentiated to acquire the myotube phenotype. The activation status of sig-
nalling molecules involved in glucose metabolism, including 5′ adenosine monophosphate-activated
protein kinase (AMPK), calcium/calmodulin-dependent protein kinase 2 (CAMKK2), extracellu-
lar signal-regulated protein kinases 1 and 2 (ERK1/2), protein kinase B (AKT), and src homology
phosphatase 2 (SHP2), was examined. Finally, activation of CAMKK2 and AMPK, and glucose oxida-
tion and ATP levels were measured in capsaicin-treated cells in the presence or absence of TRPV1
antagonist (SB-452533). Results: Capsaicin activated cell signalling molecules including CAMKK2
and AMPK leading to increased glucose oxidation and ATP generation independent of insulin in
the differentiated C2C12 cells. Pharmacological inhibition of TRPV1 diminished the activation of
CAMKK2 and AMPK as well as glucose oxidation and ATP production. Moreover, we observed an
inhibitory effect of capsaicin in the phosphorylation of ERK1/2 in the mouse myotubes. Conclusion:
Our data show that capsaicin-mediated stimulation of TRPV1 in differentiated C2C12 cells leads
to activation of CAMKK2 and AMPK, and increased glucose oxidation which is concomitant with
an elevation in intracellular ATP level. Further studies of the effect of TRPV1 channel activation by
capsaicin on glucose metabolism could provide novel therapeutic utility for the management of IR
and T2DM.
Keywords: capsaicin; TRPV1; CAMKK2; ERK1/2; glucose oxidation; ATP; skeletal muscle
1. Introduction
T2DM is a major metabolic disorder that has an enormous global impact on hu-
man health [1–3]. This debilitating disease is characterised by increased IR, a systemic
disorder of compromised ability of insulin to regulate glucose homeostasis in target pe-
ripheral tissues, including liver, adipose tissue and skeletal muscle [4].
Uncontrolled diabetes and chronic hyperglycaemia are associated with complications
that reduce life expectancy [5,6]. The risk of diabetes-related complications can be averted
by strategies that prevent or reduce the progression of IR before pancreatic beta-cell
failure. In this context, current anti-diabetic medications are associated with various side
effects which reflect substantial limitations in the current pharmacotherapy of T2DM [7–9].
Therefore, it is critical to understand novel options and their molecular pathways to
enhance the development of innovative therapies that have robust efficacy, with fewer or
no side effects for the treatment and management of T2DM.
Cells 2021, 10, 1560. https://doi.org/10.3390/cells10061560 https://www.mdpi.com/journal/cells
Cells 2021, 10, 1560 2 of 16
Emerging research on the influence of other nutrients on the regulation of glucose
metabolism has highlighted capsaicin, a phenolic active component of chilli peppers, as a
potentially effective therapy in IR and T2DM [10]. Capsaicin activates the transient receptor
potential cation channel subfamily V member 1 (TRPV1) channel [11]. TRPV1 is a nonselec-
tive calcium-permeable cation channel, involved in thermogenesis and pain-sensing and is
expressed in high metabolic rate tissues [12–15]. TRPV1 has diverse biological roles that
make this channel a potential therapeutical target in various pathophysiological conditions,
including IR and T2DM [16].
TRPV1 activation leads to increased intracellular calcium levels and several cellular
responses [15]. Elevated intracellular calcium level stimulates intracellular signalling path-
ways by CAMKK2 [17]. CAMKK2 activation in response to increased cytosolic calcium
activates phosphorylates AMPK, an energy-sensing regulatory kinase in glucose and fat
metabolism [18]. AMPK activation triggers a switch from anabolic pathways (fatty acid
synthesis, sterol synthesis, protein synthesis, and glycogen synthesis) to ATP-producing
catabolic pathways (fatty acid oxidation, mitochondrial biogenesis, glycolysis, and glucose
uptake) [19]. Moreover, AMPK activation by 5-amino-4-imidazole carboxamide riboside
(AICAR) enhances glucose uptake independently of insulin and causes an increase in
insulin sensitivity in the muscle [20,21]. AMPK activation also downregulates the phos-
phorylation and activation of ERK1/2 which improves glucose uptake in skeletal muscle
cells [22,23].
The ERK1/2-mediated cascade is a central signalling pathway that regulates various
cellular processes including cell proliferation, differentiation, and apoptosis. ERK1/2
activity is elevated in adipose tissue of rodents and humans in IR and diabetes states [24]
and is involved in the incorporation of diabetes-induced cardiac pathological changes [25].
Moreover, ERK1/2 is shown to act as a positive regulator of endoplasmic reticulum (ER)
stress in IR, and administration of the ERK1/2 inhibitor, U0126, suppresses ER stress-
induced IR in human embryonic kidney (HEK293) cells [22]. This suggests that inhibition
of the ERK1/2 pathway could be a potential novel therapeutic strategy for IR and T2DM.
In vitro and in vivo studies suggest beneficial effects of TRPV1 activation by capsaicin
on glucose homeostasis through several mechanisms [10,26]. These include the enhance-
ment of energy metabolism and insulin sensitivity through the reduction of inflammatory
factors and elevation of fatty acid oxidation, stimulation of insulin secretion from pancre-
atic beta-cells, and the activation of cell signalling molecules that are essential for glucose
uptake [10,17–19,22,27]. Regular consumption of chilli-containing foods has been shown
to reduce postprandial hyperinsulinemia in humans [28]. Capsaicin regulates cellular lipid
content by increasing fatty acid oxidation through the TRPV1-induced calcium influx and
CAMKK2/AMPK pathway in hepG2 cells [29,30]. Moreover, capsaicin increases plasma in-
sulin levels and reduces fasting glucose and inflammatory factors in animal models [10,31].
It is also shown that capsaicin administration stimulates glucose uptake in mouse C2C12
cells in an insulin-independent manner by activation of AMPK and its downstream kinase,
p38 mitogen-activated protein kinase (p38 MAPK), in these cells [32]. Insulin-independent
pathways are critical in the control of IR and provide an alternative mechanism whereby
the defect in insulin-dependent signalling could be bypassed and result in an improvement
in glycaemic control independent of insulin in skeletal muscle cells [33]. For example,
activation of AMPK mediates an increase in glucose uptake independent of insulin which
could promote glucose uptake in insulin-resistant muscle cells [34].
While attempts have been made to identify how capsaicin acts through the TRPV1
channel to improve glucose uptake, the exact molecular mechanisms remain unclear [29,30,32].
Therefore, further research is required on the mechanism of action for capsaicin-activated
TRPV1 and its effects on glucose uptake.
In the present study, we showed that capsaicin causes an increase in glucose oxi-
dation independent of insulin signalling molecules. To the best of our knowledge, this
study demonstrated for the first time capsaicin-induced CAMKK2 activation and ERK1/2
phosphorylation reduction in mouse myotubes. Moreover, we also showed that pharma-
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cological blocking of TRPV1 using SB-452533 reduces phosphorylation of CAMKK2 and
AMPK that was concomitant with a reduction in glucose oxidation and ATP levels. In
addition, capsaicin treatment diminished phosphorylation of ERK1/2 in mouse myotubes.
2. Materials and Methods
2.1. Reagents and Antibodies
Capsaicin, AICAR, and SB-452533 (TRPV1 antagonist) were purchased from Sigma
Aldrich, Australia. Antibodies pAMPKα (Thr172) (cat#2535), AMPKα (cat#5831), pCaMKK2
(Ser511) (cat#12818), CAMKK2 (cat#16810), p44/42 MAPK (pErk1/2) (Thr202/Tyr204)
(cat# 9101), p44/42 MAPK (Erk1/2) (cat#9102), pAKT (Ser473) (cat#4060), pAKT (Thr308)
(cat#13038), AKT (cat#4685), pSHP-2 (Tyr580) (cat#5431), SHP2 (cat#3397), GAPDH (cat#5174),
p-GSK-3β (Ser9) (cat#9322), GSK-3β (cat#9315), and hRP-linked secondary antibodies
(Anti-rabbit (cat#7074) and Anti-mouse (cat#7076)) were purchased from Cell Signaling
Technology, Beverly, MA, USA. TRPV1 antibody (cat#PA1-29421) and the ATP assay kit
were obtained from Thermo Fisher, Melbourne, Australia.
2.2. Differentiation Markers and TRPV1 mRNA Expression
A total of 2× 105 cells/well were seeded in 12-well plates and differentiated to myotubes
for up to 96 h. Total RNA was extracted using ISOLATE II RNA mini Kit (Bioline, Sydney,
Australia) as per manufacturer’s instructions, and cDNA was synthesised from 1 µg of total
RNA using high-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Melbourne, Aus-
tralia). Quantitative real-time PCR was performed using the SensiFAST SYBR® No-ROX Kit
(Bioline, Sydney, Australia) and the StepOnePlus™ Real-Time PCR System (Thermo Fisher, Ap-
plied Biosystems, Melbourne, Australia). PCR primers are as follows: Myogenin (Myog), 5′-
CCTTAAAGCAGAGAGCATCC-3 and 5′- GGAATTCGAGGCATAATATGA; contractile protein
troponin 1 (Tnni1), 5′- GCCTATGCGCACACCTTTG-3′ and 5′-CGGGTACCATAAGCCCACACT;
contractile protein troponin 2 (Tnni2), 5′- AAATGTTCGAGTCTGAGTCCTAACTG-3′ and 5′-
GCCAAGTACTCCCAGACTGGAT-3′; metabolic genes ATP-binding cassette subfamily A mem-
ber 1 (Abca1), 5′- GCTCTCAGGTGGGATGCAG-3′ and 5′- GGCTCGTCCAGAATGACAAC-
3′; and fatty acid-binding protein (Fabp3), 5′- CCCCTCAGCTCAGCACCAT-3′ and 5′-
CAGAAAAATCCCAACCCAAGAAT-3′ [35] Eef2, 5′- CACAATCAAATCCACCGCCAT-3′
and 5′- TGGCCTGGAGAGTCGATCA-3′ Trpv1, 5′-CCGGCTTTTTGGGAAGGGT-3 and
5′- GAGACAGGTAGGTCCATCCAC-3′ [36]. All PCR samples were assayed in triplicate
and normalised to the housekeeping gene EEF2. The average cycle threshold (Ct) value of
the three replicates was used for the comparative Ct (∆∆Ct) method, and the fold-change
values were performed using the 2−∆∆Ct method. [37].
2.3. Cell Culture
Skeletal muscle (C2C12) cells (Sigma Aldrich, Melbourne, Australia) were cultured
in 10% fetal calf serum, and 1% Penicillin-Streptomycin-supplemented DMEM contain-
ing 4500 mg/L glucose, L-glutamine, sodium pyruvate, and sodium bicarbonate (Sigma
Aldrich, Melbourne, Australia) and grown in an optimal condition of 5% CO2 at 37 ◦C. Once
the cells reached 70% confluency, the C2C12 skeletal muscle myotubule phenotype was
obtained by mitogen withdrawal (2% horse serum, Thermo Fisher, Melbourne, Australia)
for 72 h. Three hours before the treatment, the C2C12 cells were exposed to a serum-free
medium. Cells were then treated with various combinations of capsaicin, insulin, AICAR,
and SB-452533 as per the following procedures.
2.4. Cell Viability Assay
A total of 5 × 103 cells/well were seeded into 96-well plates and differentiated to
myotubes for 72 h. Following the differentiation, the cells were treated with 0, 10, 20,
50, 100, 200, and 400 µM of capsaicin for up to 120 min before the cytotoxicity effect of
capsaicin was assessed using the Vybrant® MTT Cell Proliferation Assay Kit (Thermo
Fisher, Melbourne, Australia) according to the manufacturer’s instructions. Briefly, the cell
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media was replaced with a media containing 10% MTT solution and incubated at 37 ◦C for
4 h. Following the labeling of cells with MTT, 50 µL of DMSO (Sigma Aldrich, Melbourne,
Australia) was added to each well and incubated for 10 min at 37 ◦C. The absorbance was
measured at 540 nM using a TECAN infinite M200 PRO plate reader (Tecan, Melbourne,
Australia) and the cell viability of each group was calculated with comparison to the control
group (0 µM of capsaicin).
2.5. Immunoblot Analysis of Protein Expression
A total of 4 × 105 cells/well were seeded in 6-well plates and differentiated to my-
otubes for 72 h. The cells were then treated with 100 and 200 µM of capsaicin, 10 nM
insulin, 1 and 2 mM AICAR, and different concentrations of SB-452533 for up to 60 min.
The cells were lysed with RIPA buffer (Thermo Fisher, Melbourne, Australia) containing
phosphatase and protease inhibitor cocktail, as per the manufacturer’s instructions. Total
cellular protein was extracted by centrifuging lysates at 15,000 rpm for 10 min at 4 ◦C
and total protein concentration was measured using a PierceTM BCA Protein Assay Kit
as per the manufacturer’s instructions (Thermo Fisher, Melbourne, Australia). A total of
20 µg of protein was loaded onto 4–15% mini-PROTEAN® TGX™ Precast Protein Gels
(Bio-Rad, Sydney, Australia) and transferred to a PVDF membrane using a semi-dry Turbo
Transfer System (Bio-Rad, Sydney, Australia). The membranes were blocked in 5% skim
milk in TBST buffer (20 mM Tris, 150 mM NaCl, 0.1% Tween20, pH 7.5) for 120 min
followed by overnight incubation with the specific primary antibody (pAMPKα (1:1000 di-
lution), AMPKα (1:2000 dilution), pCaMKK2 (1:1000 dilution), CAMKK2 (1:2000 dilu-
tion), pERK1/2 (1:1000 dilution), ERK1/2 (1:2000 dilution), pAKT (1:1000 dilution), AKT
(1:2000 dilution), pSHP-2 (1:1000 dilution), SHP-2 (1:2000 dilution), GAPDH (1:3000 dilu-
tion), TRPV1 (1:1000 dilution), p-GSK-3β (1:1000 dilution), GSK-3β (1:2000 dilution)) at
4 ◦C. The membranes were washed with TBST three times (5 min each time) and were then
incubated with hRP-conjugated anti-rabbit/mouse secondary antibodies (1:5000 dilution)
for 120 min. The membranes were washed again with TBST as previously described,
and the protein bands were visualised using SuperSignal™ West Femto Maximum Sen-
sitivity Substrate (Thermo Fisher, Melbourne, Australia) and a Fuji LAS-3000 imaging
system (Berthold, Australia). Non-phosphorylated proteins were used to normalise phos-
phorylated protein expression except for TRPV1, which was normalised with GAPDH.
Densitometric analysis of western blots was performed using ImageJ software.
2.6. Pharmacological Inhibition of TRPV1 and Immunoblot Analysis of AMPK and
CAMKK2 Phosphorylation
Cells were grown in 6-well plates and differentiated to myotubes for 72 h. Subse-
quently, 0, 50, 100, 200, and 400 µM of SB-452533 (TRPV1 antagonist) was added to cells
and incubated for 30 min. Cells then were treated with 200 µM capsaicin for an addi-
tional 30 min, and Western blots for p-AMPKα, AMPKα, p-CAMKK2, and CAMKK2 were
performed as previously described.
2.7. Glucose Oxidation Assay
Cells were seeded at 5 × 103 cells/well in 96-well plates and differentiated to my-
otubes for 72 h. Twenty-four hours before the assay, the myotubes medium was replaced
with minimum Essential Medium Eagle glucose-free media (Sigma Aldrich, Melbourne,
Australia). On the day of the assay, myotubes were treated for 30 min with 200 µM SB-
452533100 followed by 60 min treatment with 100 and 200 µM capsaicin, and 10 nM insulin
(positive control for glucose oxidation). The glucose oxidation assay was performed us-
ing the Glucose Uptake-GloTM Assay Kit (Promega, Sydney, Australia). Briefly, 50 µL of
0.1 mM 2DG was added to cells and incubated for 30 min at 25 ◦C. Then 25 µL of stop
buffer and neutralization buffer were added to each well and the plate was shaken briefly.
Finally, 100 µL of 2DG6P was added to each well, and the plate was incubated for 60 min
at 25 ◦C. Then, luminescence was recorded with 0.3–1 s integration on the TECAN infinite
M200 PRO plate reader and glucose oxidation level was calculated.
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2.8. Intracellular ATP Measurement
Cells were cultured into 96-well plates and differentiated to myotubes for 72 h. Cells
were treated with 0, 100, and 200 µM of capsaicin for up to 120 min. Myotubes also
were treated with 200 µM SB-452533 for 30 min followed by another 30 min incubation
with 200 µM of capsaicin to evaluate intracellular ATP content changes due to capsaicin
and SB-452533 treatment. ATP was quantified by bioluminescence assay using an ATP
determination kit (ThermoFisher, Melbourne, Australia), following the manufacturer’s
instructions.
2.9. Statistical Analysis
Data were analysed by the t-test using GraphPad Prism 8 and expressed as the
mean ± Standard Deviation (SD). p < 0.05 represents a statistically significant difference
between two groups.
3. Results
3.1. The Trpv1 mRNA and Protein Are Expressed in Skeletal Muscle Cells during
the Differentiation
Proliferating myoblasts can be differentiated into post-mitotic multinucleated my-
otubes by mitogen withdrawal. The muscle-specific contractile and metabolic phenotype
was assessed by gene expression of several important markers including the differentiation-
specific hierarchical basic helix loop regulator Myog, Tnni1, Tnni2, Abca1, and Fabp3 [34].
Myog, Tnni1, and Tnni2 mRNA expressions following 48 h of mitogen withdrawal were
significantly increased over those of time 0 (start point of differentiation) (Figure 1a–c).
Similarly, the metabolic genes Abca1 and Fabp3 were significantly induced following 96 h
of mitogen withdrawal (Figure 1d,e). These data confirmed that the C2C12 skeletal muscle
cells had acquired the differentiated and metabolic phenotype. Based on these results and
literature, we used 72 h for C2C12 differentiation [32].
Cells 2021, 10, x FOR PEER REVIEW 6 of 17 
 
 
Figure 1. Gene expression of Myog, Tnni1, Tnni2, Abca1, and Fabp3. (a–e). Quantitative real-time PCR mRNA expression 
of Myog, Tnni1, Tnni2, Abca1, and Fabp3 respectively during the differentiation of C2C12 skeletal muscle cells. Data are 
presented as the mean ± SD of three independent repeats (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 indicate 
a significant difference between differentiated and the control groups. 
We next tested for the expression of Trpv1 in mRNA and protein level in C2C12 cells 
during differentiation. The expression for Trpv1 mRNA and TRVP1 protein were similar 
during the differentiation of the C2C12 skeletal muscle cells (Figure 2a–c). 
 
Figure 2. Expression of Trpv1 mRNA and protein levels during skeletal muscle cell differentiation. (a) Quantitative real-
time PCR mRNA expression of Trpv1 during C2C12 skeletal muscle cell differentiation. (b,c) Western blot results and 
densitometric analysis of TRPV1 protein during the C2C12 differentiation, respectively. Data are presented as the mean ± 
SD of three independent repeats (n = 3). 
3.2. Capsaicin Treatment Did Not Affect Mouse Myotubes Viability 
To determine if capsaicin treatment affected cell viability, mouse C2C12 cells were 
differentiated to myotubes and treated with varying concentrations of capsaicin (0/control 
Figure 1. Gene expression of Myog, Tnni1, Tnni2, Abca1, and Fabp3. (a–e). Quantitative real-time PCR mRNA expression
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presented as the mean ± SD of three independent repeats (n = 3). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 indicate
a significant difference between differentiated and the control groups.
Cells 2021, 10, 1560 6 of 16
We next tested for the expression of Trpv1 in mRNA and protein level in C2C12 cells
during differentiation. The expression for Trpv1 mRNA and TRVP1 protein were similar
during the differentiation of the C2C12 skeletal muscle cells (Figure 2a–c).
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Figure 2. Expression of Trpv1 mRNA and protein levels during skeletal muscle cell differentiation. (a) Quantitative
real-time PCR mRNA expression of Trpv1 during C2C12 skeletal muscle cell differentiation. (b,c) Western blot results
and densitometric analysis of TRPV1 protein during the C2C12 differentiation, respectively. Data are presented as the
mean ± SD of three independent repeats (n = 3).
3.2. Capsaicin Treatment Did Not Affect Mouse Myotubes Viability
To determine if capsaicin treatment affected cell viability, mouse C2C12 cells were
differentiated to myotubes and treated with varying concentrations of capsaicin (0/control
group, 10, 20, 50, 100, 200, and 400 µM) for up to 120 min and an MTT assay was performed
as previously described on three independent experiments. The percentage of the viable
cells was then calculated. It was observed that capsaicin treatment did not significantly
affect cell viability at all concentrations over 60 min (Figure 3). however, there was a
significant reduction in cell viability in the 400 µM capsaicin-treated cells at 120 min. Ac-
cordingly, the 100 and 200 µM concentrations of capsaicin were selected for the subsequent
experiments. These concentrations are also further supported in the literature [32].
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3.3. Capsaicin Increases the Phosphorylation of Calmodulin (CAMKK2) and AMPK but
Diminishes the Phosphorylation of ERK1/2
CAMKK2 mediates AMPK phosphorylation and subsequently increases the expres-
sion and translocation of glucose transporter type 4 (GLUT4) to the cell membrane which
leads to glucose disposal into the cells through an insulin-independent pathway [18,38].
Conversely, ERK1/2 phosphorylation is reported to downregulate the AMPK pathway
and impair glucose uptake in skeletal muscle cells [22,39]. To assess CAMKK2, AMPK,
and ERK1/2 phosphorylation status by capsaicin in skeletal muscle cells, we treated cells
with 100 and 200 µM of capsaicin over 60 min. We observed a significant increase in phos-
phorylation of AMPK over 60 min in 100 and 200 µM capsaicin-treated cells (Figure 4a,b).
Capsaicin also significantly increased phosphorylation of CAMKK2 at 15, 30, and 60 min
of treatment (100 µM and 200 µM capsaicin) (Figure 4c,d), while 100 and 200 µM capsaicin
diminished the phosphorylation of ERK1/2 over 60 min incubation. We also tested the
phosphorylation status of AMPK in the presence of AICAR, the well-known AMPK activa-
tor [38]. As shown in Figure 4g, 1 and 2 mM AICAR led to phosphorylation of AMPK after
30 min of treatment.
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3.4. Capsaicin Does Not Activate Insulin Signa ling olecules
To test hether capsaici has an insulin- i etic effect in ouse yotubes, e tested
the ability of capsaicin to activate three i portant molecules involved in the insulin sig-
nalling pathway. AKT is a serine/threo ine-protein kinase that is activated by insulin
to stimulate various cellular processes including glucose metabolism [40]. SHP-2 plays a
critical role as a signal regulator in insulin-responsive cells through binding to the tyrosine-
phosphorylated insulin receptor substrate proteins [41]. Accordingly, we treated myotubes
with 100 and 200 µM of capsaicin over 60 min. Western blot analysis demonstrated that
capsaicin does not phosphorylate and activate AKT and SHP-2 over 60 min of treatment in
mouse skeletal muscle cells (Figure 5a,b). As mentioned before, insulin promotes glucose
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uptake in skeletal muscle cells by the phosphorylation of AKT, a key molecule in the
insulin signalling pathway [42]. To verify our cell system robustness, we treated cells with
10 nM insulin. Figure 5c demonstrates that 10 nM of insulin activated AKT after 30 min
of treatment.
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3.5. Capsaicin Increases Glucose Oxidation in Mouse Myotubes
It has been previously reported that capsaicin-stimulated AMPK activation leads
to an increase i gluc se uptake in mouse skeletal muscle cells [32]. We also aimed to
confirm that capsaicin’s action causes an enhancement of glucose disposal in the mouse
myotubes. Accordingly, we measured glucose oxidation in the myotubes treated with
100 and 200 µM capsaicin over 60 min. As demonstrated in Figure 6a, 100 and 200 µM
capsaicin significantly elevated glucose oxidation in myotubes over 60 min.
3.6. Capsaicin Does Not Affect Phosphorylation of GSK-3β but Increases ATP Production in
Mouse Myotubes
Following glucose uptake in skeletal muscle cells, glucose molecules can be added to
the glycogen chain for storage through glycogen sis or produce ATP during glycolysis [43].
Glycogen sy thase kinase-3 β (GSK-3β) is a serine/thre nin kinase that is involved
in several biological processes including glucose and glyc gen metabolism a d insulin
action in skeletal muscle ells [44]. Insulin inhibits the activation of GSK-3β through the
PI3K/AKT pathway which subsequently promotes gly ogen synthase (GS) activity and
glycogen synthesis in skeletal muscle cells. To evaluate th effect of capsaicin in GSK-3β
regulatio in mouse skeletal muscle cells, we treated cells with 100 and 200 µM capsaicin
and 10 nM insulin over 60 min. Then we measured the expression of p-GSK-3β and GSK-3β
in the presence or absence of capsaicin and insulin. The Western blot analysis demonstrated
that capsaicin treatments do not significantly affect GSK-3β phosphorylation. however,
insulin deactivated GSK-3β during the three different time points (Figure 6c,d). As earlier
described, AMPK activation enhances energy metabolism and glycolysis which leads to
ATP synthesis in the cells [10]. To determine the effect of capsaicin-induced ATP generation
in mouse myotubes, we treated cells with 100 and 200 µM capsaicin for 5, 15, 30, 60, and
120 min and intracellular ATP level was measured. As illustrated in Figure 6b, there is a
reduction in ATP synthesis after 15 min incubation with 100 µM of capsaicin followed by
an elevation in ATP levels over 60 min treatment. Capsaicin (200 µM) did not affect the
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ATP level after 15 min incubation but caused an increase in ATP generation between 30
and 120 min of incubation (Figure 6b).
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3.7. Capsaicin’s Action in Phosphorylation of A PK and CA KK2, and Elevation of Glucose
Oxidation and ATP Production Is through the Activation of TRPV1 Channel in Mouse Myotubes
As described previously, TRPV1 activation stimulates various signalling molecules
including AMPK and CAMKK2 that consequently regulate many cellular events [12]. To
test whether AMPK and CAMKK2 phosphorylation by capsaicin is mediated through
TRPV1 activation, we treated cells with different concentrations of the TRPV1 inhibitor,
SB-452533, for 30 min followed by 200 µM capsaicin treatment for another 30 min. Our
data demonstrate that capsaicin-induced phosphorylation of AMPK and CAMKK2 is
significantly reduced by increasing concentrations of SB-452533 treatment (Figure 7a–d).
We also demonstrated that 200 µM SB-452533 inhibits ATP production after 30 min and
reduces glucose oxidation after 60 min incubation in mouse myotubes (Figure 7e,f).
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4. Discussion
In the present study, we demonstrated that 100 and 200 µM capsaicin administration
leads to the phosphorylation of CAMKK2 and AMPK and reduces ERK1/2 phosphoryla-
tion. This was concomitant with an increase in glucose oxidation and ATP production in
mouse C2C12 skeletal muscle cells, which occurred in an insulin-independent manner and
through the activation of the TRPV1 channel (Figure 8).
Although the concentrations of capsaicin in this study are higher than blood capsaicin
concentrations (~0.2 µM) previously reported, it is important to understand the mecha-
nisms of capsaicin action on glycaemic control that may lead to the identification of novel
therapeutic targets for insulin resistance and type 2 diabetes using capsaicin analogues or
adjunct therapies that bypass defective insulin signalling pathways [45]. Capsaicin reduces
blood glucose level by enhancing insulin levels in diabetic rats [46]. Similarly, analogues of
capsaicin are efficacious in lowering blood glucose and improving glycaemic control. For
example, capsiate (a capsaicin analogue) is shown to reduce body weight gain, visceral fat
accumulation, and improve glucose tolerance in diabetic rats [47]. Another capsaicin ana-
logue (resiniferatoxin) also appears t prevent the deterioration of glucose homeostasis in
early diabetic rats [48]. Furthermore, overtly di betic rats administered with resiniferatoxin
markedly improved glucose tolerance and had an increased insulin r sponse to gluco e [48].
W ile the above studies were perf rmed in rodents, there are beneficial effects of ch lli
consumption in humans in the context of improving glucose homeostasis. For instance,
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consumption of foods containing chilli showed a beneficial effect on glucose homeostasis
in healthy adults by improving postprandial hyperglycaemia and hyperinsulinemia [28].
More specifically, chilli supplementation also improved postprandial hyperglycaemia
and hyperinsulinemia in women with gestational diabetes mellitus. Although there were
some reported minor side effects including mild diarrhea, a heat sensation in the oral cavity,
and skin weals, these reverted to normal after 2 or 3 days of supplementation [49].
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ATP production by capsaicin in skeletal muscle cells. (b) Pharmacological blocking of TRPV1 and 
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5. Conclusions 
To conclude, in this study, we demonstrated that TRPV1 activation by capsaicin 
causes an increase in glucose oxidation and ATP generation in mouse skeletal muscle 
cells. We also showed that capsaicin activates key regulators of glucose metabolism, 
CAMKK2, and AMPK in mouse myotubes. Moreover, for the first time, we demonstrated 
that capsaicin has an inhibitory effect on ERK1/2 phosphorylation which could promote 
glucose uptake in skeletal muscle cells by improving AMPK action in these cells. In con-
trast to AMPK and CAMKK2, insulin signalling molecules, AKT, and SHP-2 were not 
activated by capsaicin. Finally, for the first time, we showed that pharmacological inhibi-
tion of TRPV1 using its antagonist, SB-452533, inhibits capsaicin’s action in the phosphor-
ylation of AMPK and CAMKK2, ATP generation, and increase in glucose oxidation in the 
mouse myotubes. 
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Figure 8. Graphical summary of capsaicin-induced signal transduction in mouse skeletal muscle
cells. (a) Activation of CAMKK2 and AMPK, dephosphorylation of ERK1/2, glucose oxidation, and
ATP production by capsaicin in skeletal muscle cells. (b) Pharmacological blocking of TRPV1 and
subsequent inhibition of downstream signalling events, glucose oxidation, and ATP production in
skeletal muscle cells.
Capsaicin improves glucose homeostasis by increasing insulin sensitivity and through
the activation of important signalling lecules and the reduction of inflammatory fac-
tors [10,32]. Capsaicin has previously been shown to i crease glucose upta e independent
of insulin signalling molecules such as insulin rec ptor s bstrate 1 (IRS-1) and AKT phos-
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phorylation in C2C12 cells [10]. Similarly, our results confirmed that capsaicin’s action in
glucose metabolism is independent of activation of insulin signalling molecules such as
AKT and SHP-2 in the differentiated C2C12 cells.
AMPK activation promotes glucose uptake, glycolysis, and ATP production in skeletal
muscle cells [50]. Our data showed that capsaicin treatment activates AMPK and leads to
an increase in glucose oxidation and ATP production in the mouse myotubes. This is in
line with previous in vivo and in vitro reports in different tissues. A study on obese mouse
models demonstrated that capsaicin administration promotes mitochondrial function
and increased ATP levels in these animals [51]. Moreover, capsaicin appears to also
increase glucose metabolism and ATP production in the human intestinal epithelium [10,52].
We showed that capsaicin-induced glucose oxidation and ATP production occur via the
TRPV1 channel activation. Pharmacological inhibition of the TRPV1 channel led to a
reduction in pAMPK that was concomitant with a decrease in glucose oxidation and ATP
production in capsaicin-treated mouse myotubes. Previous studies have reported that
TRPV1 activation has beneficial effects on energy and glucose homeostasis [16]. TRPV1
activation by capsaicin reduces blood glucose concentration in mice during exercise [53]
while activated TRPV1 also increases glucose uptake in mice on high-fat diets [54]. In the
present study, we demonstrated that capsaicin promotes glucose metabolism by increasing
glucose oxidation and intracellular ATP production through the activation of TRPV1
channel in mouse myotubes. These results support the beneficial role of the TRPV1 channel
in glucose metabolism and suggest the potential therapeutic value of TRPV1 in glucose
metabolism disorders such as IR and T2DM.
A previous study reported that capsaicin activates AMPK and its downstream kinase,
p38 MAPK, leading to glucose uptake in C2C12 cells, and hypothesised that reactive oxy-
gen species (ROS) is the possible upstream activator of AMPK; however, the upstream
signalling pathway of AMPK phosphorylation remains elusive [32]. Liver kinase B1 (LKB1)
and CAMKK2 are two well-established upstream kinases implicated in the phosphoryla-
tion of AMPK on Thr172 [55]. CAMKK2 is activated in response to intracellular calcium
elevation and is involved in glucose uptake in skeletal muscle cells [17,56]. It is reported
that capsaicin-mediated AMPK activation occurs through calcium and CAMKK2 activation
in hepG2 cells [30]. To the best of our knowledge, this is the first study to show that 100
and 200 µM of capsaicin increases CAMKK2 phosphorylation in mouse myotubes. We
also demonstrated that pharmacologically inhibiting TRPV1 blocks CAMKK2 activation.
Together, these results suggest that capsaicin-mediated activation of TRPV1 and subse-
quent phosphorylation of CAMKK2 and AMPK are involved in the regulation of glucose
metabolism in mouse myotubes.
ERK1/2 activation impairs glucose uptake in smooth muscle cells by blocking IRS-1
and subsequently insulin signalling pathway in these cells [57,58]. ERK1/2 activity is also
reported to be elevated in adipose tissue of diabetic humans and rodents [24]. Moreover,
inhibitory cross-talk between AMPK and ERK1/2 pathways is associated with ER stress
and ER stress-induced IR in skeletal muscle cells [22]. Inhibition of ERK1/2 signalling
by chemical inhibitors reverses ER stress, elevates phosphorylation of AMPK, increases
glucose uptake, and eventually improves IR in myotubes [22]. This suggests that inhibition
of ERK could be a potential novel therapy for IR and T2DM. For the first time, our data
demonstrated that 100 and 200 µM of capsaicin inhibits ERK1/2 phosphorylation. This
effect of capsaicin on the downregulation of ERK1/2 could improve glucose homeostasis
through the improvement of AMPK activity and inhibition of ER stress in myotubes [22,23].
GSK3β is an important signalling molecule involved in a variety of cellular processes
including glucose transport and metabolism. It is a key regulator of GS activity. The
inhibition of GS by GSK3β causes a decrease in glycogen synthesis and a concomitant
increase in blood glucose. Insulin inhibits GSK3β activity by triggering phosphorylation of
an inhibitory serine of this kinase, in liver and skeletal muscle cells [59] and this inhibition
is associated with an increase in glucose uptake in skeletal muscle [60]. There is an
important potential role for GSK3β in the development of IR and T2DM [61,62]. GSK3β is
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overexpressed in type 2 diabetic humans and is associated with impaired glucose disposal
in these patients [63]. Moreover, GSK3β inhibitors have useful therapeutic effects on IR and
T2DM [62,63]. We evaluated the effect of capsaicin on GSK3β phosphorylation in mouse
myotubes and observed that capsaicin does not significantly affect GSK3β phosphorylation.
This is in agreeance with previous work which reported that GSK3β phosphorylation was
not affected by capsaicin administration in rat skeletal muscles [44].
TRPV1 is expressed in metabolically active tissues including liver, adipose, and skeletal
muscle [10]. Capsaicin-mediated activation of TRPV1 that facilitates cellular responses
resulting in glycaemic homeostasis, strengthens TRPV1 as an attractive target and capsaicin
as a beneficial molecule for the study of mechanisms that improve metabolic disorders
including insulin resistance and type 2 diabetes [10]. Although several studies have been
conducted to determine the molecular pathways involved in glucose metabolism that are
activated by capsaicin through the TRPV1 channel, numerous molecules and pathways
remained unknown. The presented study for the first time demonstrated that capsaicin
activates CAMKK2 in mouse myotubes which is concomitant with inhibition in ERK1/2
phosphorylation. This study also showed for the first time that pharmacological inhibition
of TRPV1 blocks AMPK and CAMKK2 phosphorylation, glucose oxidation, and ATP
production in mouse skeletal muscle cells. Future studies on capsaicin-mediated activation
of TRPV1 could lead to the development of novel and more effective therapies for the
management and treatment of IR and T2DM.
5. Conclusions
To conclude, in this study, we demonstrated that TRPV1 activation by capsaicin causes
an increase in glucose oxidation and ATP generation in mouse skeletal muscle cells. We
also showed that capsaicin activates key regulators of glucose metabolism, CAMKK2, and
AMPK in mouse myotubes. Moreover, for the first time, we demonstrated that capsaicin has
an inhibitory effect on ERK1/2 phosphorylation which could promote glucose uptake in
skeletal muscle cells by improving AMPK action in these cells. In contrast to AMPK and
CAMKK2, insulin signalling molecules, AKT, and SHP-2 were not activated by capsaicin.
Finally, for the first time, we showed that pharmacological inhibition of TRPV1 using its
antagonist, SB-452533, inhibits capsaicin’s action in the phosphorylation of AMPK and
CAMKK2, ATP generation, and increase in glucose oxidation in the mouse myotubes.
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